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Abstract 
Background: S1400B is a biomarker-driven Lung-MAP sub-study evaluating the phosphatidylinositide 3-
kinase (PI3K) inhibitor taselisib (GDC-0032) in patients with PI3K pathway-activated squamous NSCLC 
(SqNSCLC).  
Methods: Eligible patients had tumoral PIK3CA alterations by next generation sequencing and disease 
progression after at least one line of platinum-based therapy. Patients received 4 mg taselisib orally 
daily. The primary analysis population (PAP) was a subset of patients having substitution mutations 
believed to be associated with clinical benefit of PI3K inhibitors. Primary endpoint was response by 
RECIST 1.1; secondary endpoints included progression-free survival (PFS), overall survival (OS) and 
duration of response (DoR).  
Results: Twenty-six patients treated with taselisib comprised the full eligible population  
(FEP); 21 patients comprised the PAP. Median age in FEP was 68 y (53-83), 19 were male (73%). The 
study was closed for futility at interim analysis with one responder in the PAP (5% RR, 95% CI 0%-24%). 
Two possibly treatment-related deaths (1 respiratory failure, 1 cardiac arrest) were observed;  1 patient 
had Grade 4 and 11 had Grade 3 adverse events. Median PFS and OS in the PAP were 2.9 months (95% 
CI, 1.8-4.0 mos) and 5.9 months (95% CI, 4.2-7.8 mos), respectively.  These numbers were nearly the 
same in the FEP.  
Conclusions: Study S1400B evaluating taselisib in PIK3CA altered SqNSCLC failed to meet its primary 
endpoint and was closed after an interim futility analysis. The trial is unique in cataloguing the diversity 
of PIK3CA mutations in SqNSCLC. 
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Introduction 
The Lung Master Protocol (Lung-MAP, SWOG 1400) is an umbrella protocol with a screening component 
and multiple independently conducted and analyzed treatment sub-studies.[1]  Herein we report on the 
results of SWOG S1400B, a phase II Lung-MAP sub-study evaluating taselisib, a phosphoinositide-3 
kinase (PI3K) inhibitor in patients with chemo-refractory SqNSCLC tumors harboring alterations in 
PI3KCA. 
 
PI3Ks are a family of lipid kinases involved in tumor cell proliferation, survival, and migration upon 
activation by growth factor receptors and integrins. PI3Ks catalyze phosphorylation of 
phosphatidylinositol-4, 5 bisphosphate to generate phosphatidylinositol-3, 4, 5 trisphosphate, a second 
messenger involved in phosphorylation of AKT and associated proteins in the AKT/mTOR pathway. [2, 3] 
Activating and transforming mutations, as well as amplification, in the p110 alpha isoforms of PI3K are 
commonly found in solid and hematological tumors. [4] Additionally, the PI3K/AKT pathway is activated 
in numerous types of cancer by receptor tyrosine kinase signaling, loss of phosphatase and tensin 
homolog (PTEN), or RAS mutations. [2, 5-8]  PI3K alterations, including PI3K mutations and PTEN loss or 
mutations, are observed in 30%-50% of squamous lung cancers.  PI3K mutations are observed in 2-5% of 
non-squamous and in 8-10% of sqNSCLC. [7], and human tumors carrying mutated PIK3CA or deleted 
PTEN have responded favorably to PI3K inhibition. [6] 
 
Taselisib is a potent, selective small molecule inhibitor of Class 1 PI3Ks developed by Genentech as an 
anticancer therapeutic agent that is a potent growth inhibitor in nonclinical models of PI3K mutant 
tumors.[8, 9] 
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Methods 
Patients with previously treated advanced SqNSCLC were eligible for the S1400 screening study. Briefly, 
eligibility for S1400B stipulated age ≥ 18 years, Zubrod PS of 0–2 (modified to 0–1 during the study), 
measurable disease by RECIST, and adequate hematologic, hepatic, and cardiac function with no 
supplemental oxygen requirement. Calcium and phosphate levels had to be within institutional limits. 
Patients had to be able to take oral medications with no impairment of gastrointestinal function or 
gastrointestinal disease that could significantly alter the absorption of taselisib. Patients with 
leptomeningeal disease; symptomatic, untreated brain metastases; and chemotherapy within 21 days 
prior to registration were excluded.   
 
Eligibility for treatment with taselisib required base substitutions in PIK3CA (see Table 1).  The primary 
analysis population (PAP) was defined by the presence of alterations expected to derive the greatest 
benefit from PI3K inhibition. Mutational analysis was performed on archival formalin-fixed paraffin-
embedded (FFPE) tumor specimens using FoundationOne® (Foundation Medicine, Cambridge, MA). 
Tumor mutational burden (TMB) was calculated as the number of somatic, coding, short variants, 
excluding known driver mutations, per megabase of genome interrogated. 
 
Taselisib was administered orally at 4 mg qd on an empty stomach in 21 day treatment cycles. Disease 
assessment occurred every two cycles, and treatment was continued until disease progression or 
untoward toxicity. Dose reductions and adjustments were discussed with the study chair and were 
followed as specified in the protocol (Appendix). 
 
This study was originally designed as a randomized trial of taselisib versus docetaxel in the second line 
setting post progression on platinum-based treatment. However, upon approval of immunotherapy in 
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the second line setting [10-13], in December 2015, the S1400B trial was redesigned and became a single 
arm phase II study; the docetaxel arm permanently closed to accrual, and  eligibility criteria were 
modified to allow second and later lines of therapy  and only allow PS 0-1. Patients on the docetaxel arm 
were not included in the analyses presented in this paper. 
 
Statistical Considerations 
The primary objective was evaluation of the RECIST 1.1 response rate (RR; confirmed and unconfirmed, 
complete and partial) in patients in the PAP. The accrual goal was 40 response-evaluable PAP patients. 
The observation of 10/40 (25% RR) responses in the PAP was considered evidence to rule out the null RR 
and to pursue a randomized phase III trial. If at least three responses were observed on interim analysis 
of 20 evaluable patients, the trial would  continue accrual to 40 patients. Other objectives included 
assessment of response in the full evaluable population (FEP), PFS and OS in the PAP and FEP, duration 
of response (DoR) among all responders, and evaluation of the frequency and severity of toxicities in the 
FEP. A key secondary objective was investigator assessment of median PFS (mPFS) in the PAP. An RR rate 
<25% with mPFS ≥4.5 months, would have been considered sufficient evidence to continue to a follow-
on Phase III.   
Results 
Between June 16, 2014 and December 12, 2016, 55 patients (5% of those screened on S1400 while 
S1400B was actively accruing) were assigned to S1400B; 39 were enrolled, and of these, 31 were 
registered to receive taselisib. 
 
Five of those registered were deemed ineligible (2 with inadequate baseline disease assessment; 1 with 
chemotherapy within 21 days and 1 with last radiotherapy within 14 days of registration; and 1 death 
prior to treatment). Twenty-one of the 26 (81%) FEP had at least one of the PAP alterations.  Baseline 
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patient characteristics are enumerated in Table 2 and mutations for FEP and PAP are listed in Tables 1 
and 3.   
 
The most common concomitant gene alterations included mutations in TP53, MLL2, and NOTCH1, and 
copy number alterations in CDKN2A and CDKN2B (see Table 3).  The median and range TMB scores were 
9.62 (2.42-41.11), with 11 (42%) patients with TMB scores ≥10.  
 
Two on-study deaths possibly related to treatment occurred, one due to respiratory failure and one due 
to cardiac arrest. In addition, one patient experienced multiple grade 4 AEs (dyspnea, 
thrombocytopenia, and pneumonitis). Eleven additional patients experienced Grade 3 AEs including five 
patients each with hyperglycemia or diarrhea, and three with lymphopenia. Patients received a median 
of 3.5 cycles (range = 2-13, interquartile range (IQR)=2-4) of taselisib. Five patients were removed from 
treatment due to toxicity, 18 due to progression/relapse, 2 due to death, and 1 patient for other 
reasons. No patients remain on treatment.  See Table 3 for a full listing of adverse events.  
 
One patient in the PAP with an E545K gene alteration responded (5% RR, 95% Confidence Interval [CI] 
0%-24%). This patient was removed from treatment due to toxicity and subsequently exhibited disease 
progression (DoR = 4.4 months). There were no additional responses in the FEP resulting in a study-wide 
RR of 4% (95% CI, 0%-20%), but 16 patients had stable disease for a disease control rate of 65% (95% CI: 
47-84%). Figure 1 depicts the waterfall plot for individual responses by mutational status with no 
obvious pattern in terms of magnitude of change in tumor measurements or PI3K alteration type.  
In the PAP, mPFS was 2.9 months (95% CI, 1.8-4.0 mos) and median OS was 5.9 months (95% CI, 4.2-7.8 
mos).  These figures were virtually identical in the FEP (see Figure 2).  The 1- and 2-year OS estimates 
were 23.8% and 17.9% in the PAP; and 30.8% and 22.4% in the FEP.  The analysis evaluating the 
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association between patient characteristics and PFS and OS in the FEP yielded limited results.  Current 
versus former or never smokers were associated with worse prognosis (OS HR = 2.85, p=0.03) and 
number of lines of previous therapy for stage IV (0 versus 1 or more) was associated with shorter time to 
progression (HR PFS = 7.88, p = 0.006); however, this observation was based on only 3 patients with no 
prior lines of therapy for stage IV NSCLC, and these results should be interpreted with caution.  Age, 
gender, performance status, type of PI3K alteration, and tumor mutation burden were not associated 
with PFS or OS.   
 
Discussion 
The paradigm for second-line therapy for SqNSCLC has changed significantly since 2015 with the 
approval of checkpoint inhibitors of programmed death receptor pathway based on Phase III studies 
showing superior OS compared with the erstwhile standard, docetaxel. [10-13] Recently, molecular 
genotyping has become the “norm” in the evaluation of patients with advanced non-squamous NSCLC 
and has led to major interest in applying targeted agents for mutations and other genetic aberrations 
prevalent in sqNSCLC. Genetic alterations within lung adenocarcinomas and SqNSCLC are generally 
distinct. SqNSCLC tends to be genetically more complex and is usually characterized by a high overall 
mutational burden. Due to the genetic diversity and lack of clear oncogenic drivers in this disease, we 
recognized the need to develop clinical trials solely focused on SqNSCLC that could evaluate single agent 
as well as combination targeted therapies along with newer immunotherapeutic approaches.   
 
Lung-MAP sub-study S1400B was one such effort. Unfortunately, this study failed to meet its primary 
endpoint and was closed after an interim analysis for futility. The lone response observed on taselisib 
was brief; both the median PFS of 2.9 months and the median OS of 5.9 months in the targeted 
population proved disappointing. Although single agent taselisib resulted in a fair amount of 
hyperglycemia and fatigue, toxicities were manageable. The trial, though unsuccessful, proved unique in 
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cataloguing the diversity of mutations in the PI3K pathway in SqNSCLC, some of which may prove 
“targetable” in the future if a more active agent emerges. It is unclear why this agent failed.  It is 
conceivable that PI3KA is not a true driver of tumor growth in squamous NSCLC, or that bypass 
pathways circumvented the potential benefit of taselisib. Another PI3K inhibitor, buparlisib was negative 
in a broader NSCLC population with a wider range of PI3K activating mutations. [14] In contrast, taselisib 
in combination with fulvestrant yielded a modest PFS benefit of two months compared with fulvestrant 
alone in patients with estrogen receptor–positive PIK3CA mutant locally advanced or metastatic breast 
cancer. [15]  Based on the experience in breast, it is conceivable that taselisib may work better in 
combination with other agents in advanced NSCLC, but this is speculative; there are no preclinical data 
to suggest this might be the case. 
 
Also , the heterogeneity of molecular aberrations in advanced sqNSCLC suggests that targeting a single 
pathway may be insufficient.  In this regard, it should be noted that additional genetic alterations 
detailed in Table 3 were present in the majority of patients enrolled on this sub-study.  It is also posited 
that PI3K alterations may simply not be as powerful oncogenic drivers as we have observed with EGFR 
mutations and ALK rearrangements in advanced non-sqNSCLC. 
 
Though S1400B failed to identify a promising agent targeting PI3K, the study design of Lung-MAP has 
proven quite promising.  Under a single umbrella protocol, in a single disease venue, with a single IRB 
approval, we are now able to separately investigate multiple different pathways of interest, quickly 
discarding agents that prove inactive and focusing resources on new agents that may prove efficacious. 
This model of protocol design, under the aegis of the cooperative group system in the US, may be the 
most efficient means of investigating less common, as well as newly identified, oncogenic drivers. 
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Tables and Figures 
Table 1. PI3KCA Mutations in Patients Eligible for Treatment with Taselisib 
Eligible Populations Number of 
Patients 
Base Substitution Mutations Allowed*  
Full Evaluable Population (FEP) 26 R38C, R38H, E81K, R88Q, R93Q, R93W, 
P104L, P104R, G106V, G106R, 
P104_G106>R, R108H, E110del, E110K, 
K111E, K111N, K111del, G118D, V344G, 
V344M, N345K, N345I, E365K, C378F, 
E418K, C420R, E453K, E453Q, 539R, 
E542K, E542A, E542V, E542G, E542Q, 
E545A, E545G, E545K, E545Q, E545D, 
Q546E, Q546H, Q546K, Q546L, Q546P, 
Q546R, E726K, G1007R, D1017H, Y1021C, 
Y1021H, T1025A, A1035V, A1035T, 
M1043I, M1043L, M1043V, H1047L, 
H1047R, H1047Y, H1047N, H1047Q, 
G1049R, G1049S, I1058L 
Primary Analysis Population (PAP) 21 E542K, E545A, E545G, E545K, E545Q, 
H1047L, H1047R,  or H1047Y 
_______________________ 
*Base substitutions, small insertions and deletions, focal copy number amplifications, homozygous gene 
deletions, and genomic rearrangements were analyzed. Patients with disease characterized by PI3KCA 
gene amplifications and fusions were not eligible 
 
Table 2. Patient Demographics 
  All Eligible Patients Primary Analysis 
Population 
(n=26) (n=21) 
Age Median (Range) 68.1 (52.9-82.9) 70.5 (52.9-82.9) 
Male Gender 19(73%) 16(76%) 
Performance Status   
0 7(27%) 6(29%) 
1 18(69%) 14(67%) 
2 1(4%) 1(5%) 
Race/Ethnicity   
White 19(73%) 15(71%) 
Black 4(15%) 4(19%) 
Asian 1(4%) 1(5%) 
Native American 1(4%) 0(0%) 
Unknown race 1(4%) 1(5%) 
Hispanic ethnicity 1(4%) 1(5%) 
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Number of Prior Lines of 
Therapy For Stage IV 
Disease 
  
0 3(12%) 1(5%) 
1 14(54%) 12(57%) 
2 or more 9(35%) 8(38%) 
Smoking Status   
Current Smoker 8(31%) 5(24%) 
Former Smoker 17(65%) 15(71%) 
Never Smoker 1(4%) 1(5%) 
In primary analysis 
population  
21(81%) 21(100%) 
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Table 3. Gene Alterations Detected on FoundationOne® Screening in Eligible Taselisib Patients 
 Taselisib 
(n=26) 
PI3K Study Gene Alterations  
     E545K* 11(42%) 
     E542K* 6(23%) 
     H1047R* 4(15%) 
     N345K 2(8%) 
     E453K 1(4%) 
     G1049R 1(4%) 
     M1043I 1(4%) 
*Included in PAP  
Number of PI3K Gene Alterations  
     1 26(100%) 
  
Tumor Mutation Burden   
     Median 9.67 
     Range 2.42-41.11 
     Interquartile range 6.05-16.93 
  
     <10 15(58%) 
     >=10 11(42%) 
  
Other Concomitant Gene Alterations  
Short Variants  
     TP53 23(88%) 
     MLL2 8(31%) 
     NOTCH1 5(19%) 
     CDKN2A, NF1 4(15%) 
     BRAF, LRP1B, NFE2L2 3(12%) 
     FBXW7, PMS2, RB1, STK11 2(8%) 
     APC, ARID1A, ASXL1, ATR,    
     ATRX, BRCA1, BRCA2, BRIP1,  
     CDK12, CREBBP, EGFR, EP300,  
     ERBB2, FANCC, FANCD2,  
     FGFR3, GRIN2A, KDM6A,  
     MUTYH, NOTCH3, PBRM1,  
     PIK3C2G, PIK3CG, RUNX1T1,  
     SETD2, SMARCA4, SPEN,  
     STAG2, TGFBR2 
1(4%) 
Copy Number Alterations  
     CDKN2A 6(23%) 
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     CDKN2B 5(19%) 
     CCND1, FGF12, FGF19, FGF3,  
     FGF4, SOX2 
4(15%) 
     MYC, RICTOR 3(12%) 
     AKT2, FGF10, FGFR1, MDM2,  
     PIK3CA, ZNF703 
2(8%) 
     AXL, BRCA2, CCNE1, CDK4,  
     EGFR, EPHB1, ERBB2, FGFR4,  
     FLT4, KDM5A, KDM6A, KRAS,  
     NFKBIA, NKX2-1, RET, TOP1 
1(4%) 
Rearrangements  
     MAP3K13, PBRM1 1(4%) 
 
 
 
Table 4. Adverse Events Attributable to Treatment  
Adverse Event Grade of AE 
N = 26 
  3 4 5 
Cardiac arrest   1(4%) 
Dehydration 1(4%)   
Diarrhea 5(19%)   
Dyspnea 2(8%) 1(4%)  
Fatigue 3(12%)   
Hyperglycemia 5(19%)   
Hypertension 1(4%)   
Hyponatremia 1(4%)   
Hypoxia 1(4%)   
Lung infection 1(4%)   
Lymphocyte count 
decreased 
3(12%)   
Nausea 1(4%)   
Platelet count 
decreased 
 1(4%)  
Pneumonitis 1(4%) 1(4%)  
Pneumothorax 1(4%)   
Rash maculo-papular 1(4%)   
Respiratory failure   1(4%) 
Vomiting 1(4%)   
Maximum Grade of any 
AE 
11(42%) 1(4%) 2(8%) 
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Figure 1: Waterfall Plot with Annotations for Individual Alterations 
 
 
 
 
This plot depicts the response magnitude/status for all patients in the full eligible population. Patients 
who did not have a follow-up tumor disease assessment are presented at the very left of the plot 
marked with ‘inadequate response assessment’. In addition, patients who expired due to causes other 
than disease progression prior to their first disease assessment were coded as an ‘early death’ and are 
also presented at the left of the plot. Patients who had new lesions appear at their first follow-up 
assessment or who expired due to disease progression prior to the first scheduled the disease 
assessment are represented graphically as a 100% increase in tumor burden.  For the remaining patients 
with follow-up disease assessments, the vertical bars represent the best percent decrease in tumor 
burden when compared to baseline as defined by RECIST 1.1. Negative numbers represent decrease in 
tumor burden from baseline while positive numbers represent increase in tumor burden from baseline. 
‘+’ indicates a patient was in the primary analysis population (PAP).  
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Figure 2. Kaplan-Meier Plots of PFS and OS in the Full Eligible Population (FEP) 
2a. PFS 
 
 
 
2B. OS 
 
 Survival distributions were estimated using the Kaplan-Meier method and the Brookmeyer-Crowley 
method was used to estimate confidence intervals.   
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Figure 3. Forest Plot Comparison of Patient Characteristics and PFS and OS in the Full Eligible 
Population (FEP) 
3A. Forest Plot for PFS.  
 
3B. Forest Plot for OS. 
 
 
The Brookmeyer-Crowley method was used to estimate confidence intervals.   
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